News Updates‎ > ‎

Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment

posted Aug 10, 2012, 10:33 AM by dm gillis
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the “Company” or “Lightlake”), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company’s proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED). BED is a psychiatric condition that is manifested by recurrent episodes of eating unusually large amounts of food in a short period of time associated with a sense of lack of control over food intake. Read more